vs
美国运通（AXP）与CytomX Therapeutics, Inc.（CTMX）财务数据对比。点击上方公司名可切换其他公司
美国运通的季度营收约是CytomX Therapeutics, Inc.的1013.3倍（$18.9B vs $18.7M），美国运通净利率更高（15.7% vs -0.8%，领先16.5%），美国运通同比增速更快（11.4% vs -25.7%），过去两年美国运通的营收复合增速更高（38.8% vs -15.9%）
美国运通是全球知名的支付服务提供商，主营签账卡、信用卡产品及旅行相关服务，下设全球消费者服务、全球商业服务、全球商户与网络服务三大业务板块，还提供支付融资、网络服务、应付账款费用管理、旅行生活服务等多元解决方案。
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
AXP vs CTMX — 直观对比
营收规模更大
AXP
是对方的1013.3倍
$18.7M
营收增速更快
AXP
高出37.1%
-25.7%
净利率更高
AXP
高出16.5%
-0.8%
两年增速更快
AXP
近两年复合增速
-15.9%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9B | $18.7M |
| 净利润 | $3.0B | $-154.0K |
| 毛利率 | — | — |
| 营业利润率 | — | -6.9% |
| 净利率 | 15.7% | -0.8% |
| 营收同比 | 11.4% | -25.7% |
| 净利润同比 | 15.0% | 97.6% |
| 每股收益（稀释后） | $4.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXPCTMX
| Q1 26 | $18.9B | — | ||
| Q4 25 | $10.9B | — | ||
| Q3 25 | $10.4B | — | ||
| Q2 25 | $10.3B | $18.7M | ||
| Q1 25 | $9.6B | $50.9M | ||
| Q4 24 | $10.0B | $38.1M | ||
| Q3 24 | $9.7B | $33.4M | ||
| Q2 24 | $9.8B | $25.1M |
净利润AXPCTMX
| Q1 26 | $3.0B | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $2.9B | $-154.0K | ||
| Q1 25 | $2.6B | $23.5M | ||
| Q4 24 | $2.2B | $18.9M | ||
| Q3 24 | $2.5B | $5.7M | ||
| Q2 24 | $3.0B | $-6.5M |
营业利润率AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | — | ||
| Q3 25 | 36.7% | — | ||
| Q2 25 | 34.4% | -6.9% | ||
| Q1 25 | 34.6% | 44.4% | ||
| Q4 24 | 27.7% | 46.4% | ||
| Q3 24 | 33.0% | 12.3% | ||
| Q2 24 | 38.6% | -33.7% |
净利率AXPCTMX
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 27.9% | — | ||
| Q2 25 | 28.0% | -0.8% | ||
| Q1 25 | 26.8% | 46.2% | ||
| Q4 24 | 21.8% | 49.6% | ||
| Q3 24 | 25.8% | 17.2% | ||
| Q2 24 | 30.7% | -26.0% |
每股收益（稀释后）AXPCTMX
| Q1 26 | $4.28 | — | ||
| Q4 25 | $3.52 | — | ||
| Q3 25 | $4.14 | — | ||
| Q2 25 | $4.08 | — | ||
| Q1 25 | $3.64 | — | ||
| Q4 24 | $3.04 | — | ||
| Q3 24 | $3.49 | — | ||
| Q2 24 | $4.15 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $49.0M |
| 总债务越低越好 | $60.4M | — |
| 股东权益账面价值 | $34.0M | $119.9M |
| 总资产 | $308.9M | $175.1M |
| 负债/权益比越低杠杆越低 | 1.78× | — |
8季度趋势，按日历期对齐
现金及短期投资AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $197.0M | $49.0M | ||
| Q1 25 | $261.0M | $47.6M | ||
| Q4 24 | $221.0M | $38.1M | ||
| Q3 24 | $120.0M | $40.6M | ||
| Q2 24 | $188.0M | $43.2M |
总债务AXPCTMX
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | — | ||
| Q2 24 | $51.5B | — |
股东权益AXPCTMX
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | — | ||
| Q3 25 | $32.4B | — | ||
| Q2 25 | $32.3B | $119.9M | ||
| Q1 25 | $31.2B | $25.0M | ||
| Q4 24 | $30.3B | $-456.0K | ||
| Q3 24 | $29.7B | $-23.5M | ||
| Q2 24 | $29.5B | $-31.2M |
总资产AXPCTMX
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | — | ||
| Q3 25 | $297.6B | — | ||
| Q2 25 | $295.6B | $175.1M | ||
| Q1 25 | $282.2B | $98.5M | ||
| Q4 24 | $271.5B | $120.5M | ||
| Q3 24 | $271.0B | $139.0M | ||
| Q2 24 | $272.2B | $159.2M |
负债/权益比AXPCTMX
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | — | ||
| Q2 24 | 1.74× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-15.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-15.8M |
| 自由现金流率自由现金流/营收 | — | -84.6% |
| 资本支出强度资本支出/营收 | — | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-77.7M |
8季度趋势，按日历期对齐
经营现金流AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $4.4B | $-15.8M | ||
| Q1 25 | $4.8B | $-21.0M | ||
| Q4 24 | $5.8B | $-19.9M | ||
| Q3 24 | $-1.8B | $-20.7M | ||
| Q2 24 | $4.5B | $-19.5M |
自由现金流AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $5.6B | — | ||
| Q2 25 | $3.7B | $-15.8M | ||
| Q1 25 | $4.3B | $-21.2M | ||
| Q4 24 | $5.3B | $-20.0M | ||
| Q3 24 | $-2.3B | $-20.7M | ||
| Q2 24 | $4.0B | $-19.6M |
自由现金流率AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | — | ||
| Q3 25 | 53.6% | — | ||
| Q2 25 | 36.3% | -84.6% | ||
| Q1 25 | 45.0% | -41.6% | ||
| Q4 24 | 53.1% | -52.5% | ||
| Q3 24 | -23.3% | -62.1% | ||
| Q2 24 | 40.4% | -78.2% |
资本支出强度AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 6.0% | 0.1% | ||
| Q1 25 | 4.5% | 0.2% | ||
| Q4 24 | 5.0% | 0.2% | ||
| Q3 24 | 4.7% | 0.1% | ||
| Q2 24 | 5.8% | 0.4% |
现金转化率AXPCTMX
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | -0.89× | ||
| Q4 24 | 2.66× | -1.05× | ||
| Q3 24 | -0.72× | -3.61× | ||
| Q2 24 | 1.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXP
暂无分部数据
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
